2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Bohloeki ≥98.0% Olaparib Intermediate Factory
Bohloeki bo Phahameng, Tlhahiso ea Khoebo
Olaparib le Li-intermediate tse Amanang le tsona:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
Lebitso la Lik'hemik'hale | 2-Fluoro-5-Formylbenzonitrile |
Litlhaloso tse tšoanang | 3-Cyano-4-Fluorobenzaldehyde |
Nomoro ea CAS | 218301-22-5 |
Nomoro ea KAtse | RF-PI451 |
Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
Foromo ea limolek'hule | C8H4FNO |
Boima ba Molek'hule | 149.12 |
Melting Point | 80.0 ho isa ho 84.0℃ (lit.) |
Solubility | E qhibiliha ka Methanol |
Brand | Ruifu Chemical |
Ntho | Litlhaloso |
Ponahalo | Phofo e mosehla ho isa ho e tšoeu |
Bohloeki | ≥98.0% |
Mongobo (KF) | ≤0.50% |
Litšila ka Kakaretso | ≤2.0% |
Tekanyetso ea Teko | Maemo a Khoebo |
Tšebeliso | Bohareng ba Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Sephutheloana: Botlolo, Aluminium foil bag, Cardboard Drum, 25kg/Drum, kapa ho latela tlhoko ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) e sebelisetsoa ho lokisetsa metsoako ea heterocyclic e le PARP inhibitors bakeng sa tšebeliso ea meriana.2-Fluoro-5-Formylbenzonitrile e sebelisoa e le bohareng ba Olaparib (CAS: 763113-22-0).Olaparib ke inhibitor e nyane ea molek'hule ea PARP1/PARP2 (IC50: 5/1 nM) empa ha e sebetse hantle khahlano le PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, lebitso la khoebo Lynparza) ke kalafo e amohetsoeng ke FDA bakeng sa mofetše, e ntlafalitsoeng ke KuDOS Pharmaceuticals mme hamorao ke AstraZeneca.Ke PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), enzyme e amehang ho lokisoeng ha DNA. E sebetsa khahlanong le mofets'e ho batho ba nang le liphetoho tsa lefutso tsa BRCA1 kapa BRCA2, tse kenyelletsang mofets'e o mong oa mahe a bomme, matsoele le prostate.Ka Tšitoe 2014, olaparib e ile ea lumelloa ho sebelisoa e le moemeli a le mong ke EMA le FDA.Tumello ea FDA e mabapi le mofetše oa BRCA mutated (gBRCAm) o tsoetseng pele oa kankere ea mahe e fumaneng mela e meraro kapa ho feta ea chemotherapy.